Radiofrequency Ablation and Chemotherapy With Bile Duct Stenting for Unresectable Cholangiocarcinoma
Led by Universitätsklinikum Hamburg-Eppendorf · Updated on 2026-09-09
130
Participants Needed
9
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the use of radiofrequency ablation RFA in patients with unresectable bile duct cancer who are receiving systemic chemotherapy and bile duct stenting. The study aims to determine whether adding RFA to standard treatment can reduce complications such as stent dysfunction, delays in chemotherapy, and infections, while also assessing the safety of RFA in these patients. Participants have unresectable perihilar or ductal cholangiocarcinoma and are undergoing palliative systemic therapy.
Participants are divided into two groups one group will receive systemic chemotherapy and bile duct stenting along with intraductal radiofrequency ablation of malignant bile duct obstructions before stent placement, while the other group will receive systemic chemotherapy and bile duct stenting without RFA. The treatment uses a CE-certified ablation catheter delivered via catheter and transpapillary access. All participants receive standard care, and the study compares outcomes between those who receive RFA and those who do not.
During the trial, researchers will monitor participants for up to six months, focusing on the time to first stent dysfunction event. They will also assess overall survival for up to 30 months, patient satisfaction using quality of life questionnaires, treatment-emergent adverse events, clinical event rates, and days spent in hospital overnight. Participants will be followed regularly to evaluate these outcomes and ensure safety throughout the study period.
CONDITIONS
Brief Title
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
Research Team
P
Project Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with unresectable perihilar or ductal cholangiocarcinoma requiring bile duct stenting and palliative systemic therapy
Able to give written informed consent
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
At least 18 years old
Eligible for palliative systemic therapy based on clinical and laboratory parameters except hyperbilirubinemia
No prior radiofrequency ablation for cholangiocarcinoma
No repeated bile duct stenting in the past 3 months unless first stent replacement or initial stent placement
No other disease or cancer that interferes with study procedures or outcomes, including severe or uncontrolled heart disease and psychiatric disorders preventing informed consent
You will not qualify if you...
Prior radiofrequency ablation treatment for cholangiocarcinoma
Repeated bile duct stenting within the past 3 months except for first stent replacement or initial placement
Severe or uncontrolled cardiovascular disease such as congestive heart failure NYHA III or IV, unstable angina, recent myocardial infarction within 3 months, or significant arrhythmias
Psychiatric disorders that prevent understanding of trial information and informed consent
Other concomitant diseases or malignancies that interfere with study procedures or outcome measurements
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 6 months
Participants receive systemic chemotherapy and bile duct stenting. One group also receives radiofrequency ablation of malignant bile duct obstructions before stent placement.
Regular visits for treatment and monitoring
Follow-up
Duration - Up to 30 months
Participants are monitored for stent function, overall survival, quality of life, adverse events, and hospital stays for up to 30 months after treatment.
Periodic assessments and questionnaires
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Building a Biological Collection to Create Preclinical Models for Studying Liver Tumors and Chronic Liver Diseases
Using 3D Ultrasound Imaging to Guide Ablation or Biopsy Treatment for Liver and Kidney Tumors
Evaluation of 18FFAPI-74 PET Imaging Compared to Standard Methods for Detecting Multiple Cancer Types
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Developing Advanced 4D-MRI Imaging to Improve Radiation Therapy for Lung and Liver Cancer
Including Healthy Adult Volunteers for Imaging Research
Phase 2 Study of 68Ga-PSMA-11 PET-Guided Radioligand Therapy with 177Lu-PSMA-617 in Adults with Metastatic Hepatocellular Carcinoma
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Imaging PARP Expression Using 18FFTT PETCT to Predict Response to Gemcitabine, Cisplatin, and Durvalumab in Newly Diagnosed Cholangiocarcinoma
Phase I Study of Intravenous CEA-Targeted CAR-T Therapy for Advanced CEA Positive Solid Tumors
French Multicenter Study on Rare Primary Liver Cancers
Describing Clinical Features and Treatment Outcomes
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trial.
Constantin Schmidt, Antonia Zapf, Ann-Kathrin Ozga...